Organon Believes It Can Beat Out Other Humira Rivals In US

PBMs Likely To List ‘Two Or Three’ Adalimumab Biosimilars On Formulary

 
• By David Wallace
  
Red Chess Pawn Standing Out From Row Of Black Pawns
Organon thinks it can stand out from the competition on adalimumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products